PAPZIMEOS crosses the chasm: Precigen turns its first profit before the drug's first approval anniversary

Q2 PAPZIMEOS revenue of $53.1M (≈145% QoQ) flips the income statement positive; stock +73% in 90 days, near a multi-year high

PGEN · Earnings Call · 2026-08-04

Precigen's Q2 2026 print, reported on August 4, is one of those rare transition points where a biotech stops being a pipeline story and becomes a commercial one. PAPZIMEOS — the first FDA-approved therapy for adult recurrent respiratory papillomatosis, now carrying 7-year market exclusivity into August 2032 — generated PAPZIMEOS revenue of $53.1M in the quarter, up from $21.6M in Q1, a jump of more than 145% quarter-over-quarter. As Helen Sabzevari framed it, that single line propelled the company into net profitability: “PAPZIMEOS revenue in Q2 propelled the company to a quarterly net profit even before we reached the first anniversary of FDA approval.” — Helen Sabzevari, President and Chief Executive Officer · 2026-08-04 PAPZIMEOS is now being embedded as a first-line approved therapy, prescribed across severities and not just for the most severe cases. The company's keyword trajectory captures the pivot from clinical milestones — BLA submission, PDUFA date, Complete responders — to commercial vocabulary: this quarter's board is led by growth story, alongside patient access, hub registrations and payer expansion. The narrative has decisively moved from 'will it be approved' to 'how fast can it scale.'

The inflection is in the numbers, not just the narrative

The fundamentals file lags the call by a quarter (period ended April 30), which makes the turn look even sharper. Total revenue was $23M in Q1 2026, barely above the $1M posted a year earlier — and the Q2 call nearly 2.4x'd that with $55M. More consequential: net income swung from -$8M in Q1 to +$20.1M in Q2 on $22.6M of operating income and a 95% gross margin. That margin is flattered by cheap prelaunch inventory — management guides to the high-80s/low-90s after Q3 — but the underlying unit economics are the point: a subcutaneous immunotherapy with COGS around 10% of revenue is a structurally high-margin franchise.

Commercial machinery and durable demand

Revenue durability rests on commercial infrastructure. Payer coverage now reaches roughly 315 million lives, adding about 18 million in Q2, and the permanent J-code, effective April 1, has unblocked accounts that had been waiting for reimbursement certainty.

we've seen from other launch analogs that the J-code can have an impact. ... Tangibly, we've seen some institutions that we knew were holding back and waiting for the permanent J-code. And as you would imagine, they've now come on board and are starting to identify patients.
Phil Tennant, Commercial Leader · 2026-08-04

The Precigen Hub has registered more than 500 patients, with over 200 dosed and more than 100 completing the full four-dose course — and a 'meaningful proportion' of treated patients comes through non-hub institutions, a sign adoption is spreading into routine community practice. The disclosure cadence is telling: in May, Phil Tennant declined specifics on dosed patients — “we're not commenting on the specific number of patients who have actually been initiated on treatment” — Phil Tennant, Chief Commercial Officer · 2026-05-13 — yet four months later he cites 200+ dosed and 100+ completers. The confidence traces to durability data: 83% of patients in ongoing complete response beyond three years at the ASCO cutoff, with Sabzevari emphasizing “these durable complete responders have not received any treatment for RRP after receiving PAPZIMEOS” — Helen Sabzevari, President and Chief Executive Officer · 2026-08-04. On the demand mix, Phil was blunt about what drives near-term growth: “for the next few quarters, the bulk of the revenue that we will win is going to be new demand. There's definitely a carryover factor quarter-over-quarter, but it's new demand that is driving the business.” — Phil Tennant, Commercial Leader · 2026-08-04 The balance sheet provides the final proof point. Harry Thomasian reiterated that cash plus receivables will fund operations through cash-flow breakeven by year-end: “based on our current financial forecast, our cash, cash equivalents and investments, along with the collection of PAPZIMEOS receivables will fund operations through cash flow breakeven by the end of 2026.” — Harry Thomasian, Chief Financial Officer · 2026-08-04 That matters because effective net cash was just $6M at the Q1 trough — the $71.9M trade receivables balance is a genuine liquidity bridge to self-funding. In November 2025, Phil had promised “when we report our Q4 earnings, we'll be able to talk specifically to numbers of dosed and of course the earnings and the revenues that go along with that” — Phil Tennant, Chief Commercial Officer · 2025-11-13; the promise has now been more than delivered.

Idiosyncratic in a tariff-soaked tape

The contrast with the broader market is stark. The global earnings-call keyword set is saturated with macro themes — IEEPA refunds, tariff-refund benefits, grid mechanics like 'Batch Zero' — and a wave of reporters this week (including Apple, Baxter and Gildan) are booking tariff-refund benefits. PGEN has none of that bookkeeping noise: its beat is a first-in-class gene-therapy launch, entirely idiosyncratic. In a market starved for genuine Earnings growth, PGEN delivered it the hard way — from a near-zero revenue base to its first quarterly net profit. The tape agrees with the fundamentals. The 90-day price series is up roughly 73%, with the last close within about 3% of its high (drawdown ≈ -3.2%) — after a brutal multi-year slide that took the stock down nearly 89% from its 2015 peak. Investors are voting that the approval-to-commercial crossover is real, though at a ~$1.5 billion market cap still down ~70% on a ten-year basis, the re-rating is young. Beyond the launch sits platform optionality: the same AdenoVerse backbone is advancing in PRGN-2009 for HPV-16/18-driven head-and-neck and cervical cancers (head-and-neck data promised later this year), the EMA is reviewing the PAPZIMEOS marketing application, and a pediatric trial is slated to begin this year. Those are call options on a platform that just proved itself commercially. For now, the headline is the inflection — a company that reached net profitability before its first approved product's one-year anniversary, telling a coherent, evidence-backed growth story to back it up.